Selected research
Market Outlook & Growth Opportunities
Global Aptamer CDMO Market Outlook and Growth Opportunities 2026
Market perspective
The global Aptamer CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Aptamer CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Aptamer CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Aptamer CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Aptamer CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Aptamer CDMO market include AMSBIO, Aptagen, Aptamer Group, PORTON, Base Pair, Base Pair Biotechnologies, Cambio, CD Bioparticles and Creative Biolabs, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.
This report provides an overview of the global Aptamer CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Aptamer CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Aptamer CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Aptamer CDMO market.
Aptamer CDMO Segment by Company
AMSBIO
Aptagen
Aptamer Group
PORTON
Base Pair
Base Pair Biotechnologies
Cambio
CD Bioparticles
Creative Biolabs
Eurogentec
Novaptech
Aptamer CDMO Segment by Type
RNA Aptamer CDMO
DNA Aptamer CDMO
Others
Aptamer CDMO Segment by Application
Scientific Research
Medical Treatment
Others
Aptamer CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Aptamer CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Aptamer CDMO key companies, revenue, market share, and recent developments.
3. To split the Aptamer CDMO breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Aptamer CDMO market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Aptamer CDMO significant trends, drivers, influence factors in global and regions.
6. To analyze Aptamer CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aptamer CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Aptamer CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aptamer CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Aptamer CDMO industry.
Chapter 3: Detailed analysis of Aptamer CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Aptamer CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Aptamer CDMO in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Aptamer CDMO
- DNA Aptamer CDMO
- Others
Applications
- Scientific Research
- Medical Treatment
- Others
Companies covered
- AMSBIO
- Aptagen
- Aptamer Group
- PORTON
- Base Pair
- Base Pair Biotechnologies
- Cambio
- CD Bioparticles
- Creative Biolabs
- Eurogentec
- Novaptech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Aptamer CDMO Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Aptamer CDMO Market Size (2021-2032)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Aptamer CDMO Market Dynamics
- 2.1 Aptamer CDMO Industry Trends
- 2.2 Aptamer CDMO Industry Drivers
- 2.3 Aptamer CDMO Industry Opportunities and Challenges
- 2.4 Aptamer CDMO Industry Restraints
3 Aptamer CDMO Market by Company
- 3.1 Global Aptamer CDMO Company Revenue Ranking in 2025
- 3.2 Global Aptamer CDMO Revenue by Company (2021-2026)
- 3.3 Global Aptamer CDMO Company Ranking (2024-2026)
- 3.4 Global Aptamer CDMO Company Manufacturing Base and Headquarters
- 3.5 Global Aptamer CDMO Company Product Type and Application
- 3.6 Global Aptamer CDMO Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Aptamer CDMO Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.7.3 2025 Aptamer CDMO Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
4 Aptamer CDMO Market by Type
- 4.1 Aptamer CDMO Type Introduction
- 4.1.1 RNA Aptamer CDMO
- 4.1.2 DNA Aptamer CDMO
- 4.1.3 Others
- 4.2 Global Aptamer CDMO Sales Value by Type
- 4.2.1 Global Aptamer CDMO Sales Value by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Aptamer CDMO Sales Value by Type (2021-2032)
- 4.2.3 Global Aptamer CDMO Sales Value Share by Type (2021-2032)
5 Aptamer CDMO Market by Application
- 5.1 Aptamer CDMO Application Introduction
- 5.1.1 Scientific Research
- 5.1.2 Medical Treatment
- 5.1.3 Others
- 5.2 Global Aptamer CDMO Sales Value by Application
- 5.2.1 Global Aptamer CDMO Sales Value by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Aptamer CDMO Sales Value by Application (2021-2032)
- 5.2.3 Global Aptamer CDMO Sales Value Share by Application (2021-2032)
6 Aptamer CDMO Regional Value Analysis
- 6.1 Global Aptamer CDMO Sales Value by Region: 2021 VS 2025 VS 2032
- 6.2 Global Aptamer CDMO Sales Value by Region (2021-2032)
- 6.2.1 Global Aptamer CDMO Sales Value by Region: 2021-2026
- 6.2.2 Global Aptamer CDMO Sales Value by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Aptamer CDMO Sales Value (2021-2032)
- 6.3.2 North America Aptamer CDMO Sales Value Share by Country, 2025 VS 2032
- 6.4 Europe
- 6.4.1 Europe Aptamer CDMO Sales Value (2021-2032)
- 6.4.2 Europe Aptamer CDMO Sales Value Share by Country, 2025 VS 2032
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Aptamer CDMO Sales Value (2021-2032)
- 6.5.2 Asia-Pacific Aptamer CDMO Sales Value Share by Country, 2025 VS 2032
- 6.6 South America
- 6.6.1 South America Aptamer CDMO Sales Value (2021-2032)
- 6.6.2 South America Aptamer CDMO Sales Value Share by Country, 2025 VS 2032
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Aptamer CDMO Sales Value (2021-2032)
- 6.7.2 Middle East & Africa Aptamer CDMO Sales Value Share by Country, 2025 VS 2032
7 Aptamer CDMO Country-level Value Analysis
- 7.1 Global Aptamer CDMO Sales Value by Country: 2021 VS 2025 VS 2032
- 7.2 Global Aptamer CDMO Sales Value by Country (2021-2032)
- 7.2.1 Global Aptamer CDMO Sales Value by Country (2021-2026)
- 7.2.2 Global Aptamer CDMO Sales Value by Country (2027-2032)
- 7.3 USA
- 7.3.1 USA Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.3.2 USA Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.3.3 USA Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.4 Canada
- 7.4.1 Canada Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.4.2 Canada Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.4.3 Canada Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.5 Mexico
- 7.5.1 Mexico Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.5.2 Mexico Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.5.3 Mexico Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.6 Germany
- 7.6.1 Germany Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.6.2 Germany Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Germany Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.7 France
- 7.7.1 France Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.7.2 France Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.7.3 France Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.8 U.K.
- 7.8.1 U.K. Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.8.2 U.K. Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.8.3 U.K. Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.9 Italy
- 7.9.1 Italy Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.9.2 Italy Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.9.3 Italy Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.10 Spain
- 7.10.1 Spain Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.10.2 Spain Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.10.3 Spain Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.11 Russia
- 7.11.1 Russia Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.11.2 Russia Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Russia Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.12 Netherlands
- 7.12.1 Netherlands Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.12.2 Netherlands Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Netherlands Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.13.2 Nordic Countries Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Nordic Countries Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.14 China
- 7.14.1 China Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.14.2 China Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.14.3 China Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.15 Japan
- 7.15.1 Japan Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.15.2 Japan Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Japan Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.16 South Korea
- 7.16.1 South Korea Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.16.2 South Korea Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.16.3 South Korea Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.17 India
- 7.17.1 India Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.17.2 India Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.17.3 India Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.18 Australia
- 7.18.1 Australia Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.18.2 Australia Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.18.3 Australia Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.19.2 Southeast Asia Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.19.3 Southeast Asia Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.20 Brazil
- 7.20.1 Brazil Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.20.2 Brazil Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Brazil Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.21 Argentina
- 7.21.1 Argentina Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.21.2 Argentina Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Argentina Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.22 Chile
- 7.22.1 Chile Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.22.2 Chile Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Chile Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.23 Colombia
- 7.23.1 Colombia Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.23.2 Colombia Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Colombia Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.24 Peru
- 7.24.1 Peru Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.24.2 Peru Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Peru Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.25.2 Saudi Arabia Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Saudi Arabia Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.26 Israel
- 7.26.1 Israel Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.26.2 Israel Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Israel Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.27 UAE
- 7.27.1 UAE Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.27.2 UAE Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.27.3 UAE Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.28 Turkey
- 7.28.1 Turkey Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.28.2 Turkey Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Turkey Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.29 Iran
- 7.29.1 Iran Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.29.2 Iran Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.29.3 Iran Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
- 7.30 Egypt
- 7.30.1 Egypt Aptamer CDMO Sales Value Growth Rate (2021-2032)
- 7.30.2 Egypt Aptamer CDMO Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Egypt Aptamer CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 AMSBIO
- 8.1.1 AMSBIO Company Information
- 8.1.2 AMSBIO Business Overview
- 8.1.3 AMSBIO Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.1.4 AMSBIO Aptamer CDMO Product Portfolio
- 8.1.5 AMSBIO Recent Developments
- 8.2 Aptagen
- 8.2.1 Aptagen Company Information
- 8.2.2 Aptagen Business Overview
- 8.2.3 Aptagen Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.2.4 Aptagen Aptamer CDMO Product Portfolio
- 8.2.5 Aptagen Recent Developments
- 8.3 Aptamer Group
- 8.3.1 Aptamer Group Company Information
- 8.3.2 Aptamer Group Business Overview
- 8.3.3 Aptamer Group Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.3.4 Aptamer Group Aptamer CDMO Product Portfolio
- 8.3.5 Aptamer Group Recent Developments
- 8.4 PORTON
- 8.4.1 PORTON Company Information
- 8.4.2 PORTON Business Overview
- 8.4.3 PORTON Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.4.4 PORTON Aptamer CDMO Product Portfolio
- 8.4.5 PORTON Recent Developments
- 8.5 Base Pair
- 8.5.1 Base Pair Company Information
- 8.5.2 Base Pair Business Overview
- 8.5.3 Base Pair Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.5.4 Base Pair Aptamer CDMO Product Portfolio
- 8.5.5 Base Pair Recent Developments
- 8.6 Base Pair Biotechnologies
- 8.6.1 Base Pair Biotechnologies Company Information
- 8.6.2 Base Pair Biotechnologies Business Overview
- 8.6.3 Base Pair Biotechnologies Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.6.4 Base Pair Biotechnologies Aptamer CDMO Product Portfolio
- 8.6.5 Base Pair Biotechnologies Recent Developments
- 8.7 Cambio
- 8.7.1 Cambio Company Information
- 8.7.2 Cambio Business Overview
- 8.7.3 Cambio Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.7.4 Cambio Aptamer CDMO Product Portfolio
- 8.7.5 Cambio Recent Developments
- 8.8 CD Bioparticles
- 8.8.1 CD Bioparticles Company Information
- 8.8.2 CD Bioparticles Business Overview
- 8.8.3 CD Bioparticles Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.8.4 CD Bioparticles Aptamer CDMO Product Portfolio
- 8.8.5 CD Bioparticles Recent Developments
- 8.9 Creative Biolabs
- 8.9.1 Creative Biolabs Company Information
- 8.9.2 Creative Biolabs Business Overview
- 8.9.3 Creative Biolabs Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.9.4 Creative Biolabs Aptamer CDMO Product Portfolio
- 8.9.5 Creative Biolabs Recent Developments
- 8.10 Eurogentec
- 8.10.1 Eurogentec Company Information
- 8.10.2 Eurogentec Business Overview
- 8.10.3 Eurogentec Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.10.4 Eurogentec Aptamer CDMO Product Portfolio
- 8.10.5 Eurogentec Recent Developments
- 8.11 Novaptech
- 8.11.1 Novaptech Company Information
- 8.11.2 Novaptech Business Overview
- 8.11.3 Novaptech Aptamer CDMO Revenue and Gross Margin (2021-2026)
- 8.11.4 Novaptech Aptamer CDMO Product Portfolio
- 8.11.5 Novaptech Recent Developments
9 Concluding Insights
10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst